常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-22.75/-9.78
|
|
企业价值
722.09M
|
| 资产负债 |
|
每股账面净值
15.49
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
61.00K
|
|
每股收益
2.28
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others. |

30.78 
